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The possible interaction between exogenous 
reproductive hormones and athletic performance 
in females is an important issue that has been the 
topic of debate for at least four decades1.  ere 
are numerous review articles on the e ect of oral 
contraceptives (OC) on athletic performance2-6, 
however we feel that these reviews are insu  cient 
as they do not include all categories of hormonal 
contraceptives. In addition to OCs, there are many 
other delivery systems for hormonal contraceptives 
including Intrauterine Devices (IUDs), injections, 
transdermal patches, implants and vaginal rings. 
TABLE 1 shows the characteristics of each type of 
hormonal contraceptive.
Most hormonal contraceptives contain the synthetic 
oestrogen Ethinyl Estradiol (EE), however there are 
four generations of progestins, each with varying 
androgenicity and potency; for a comprehensive 
review see Benagiano et al.7. Each type of hormonal 
contraceptive has multiple formulations and brands 
that supply oestrogens and/or progestins in various 
concentrations for di erent durations8. As such, the 
term “hormonal contraceptives” is an umbrella phrase 
that refers to any type of exogenous hormones that 
alters endogenous endocrine function and prevents 
pregnancy8.  is is the  rst paper to consider the 
e ects of a large variety of hormonal contraceptives 
on athletic performance, as opposed to focussing on 
OCs as previous reviews have. 
Recent data suggest that ~22% of the general 
population uses OCs, with ~9% using other forms of 
hormonal contraceptives9. In athletes, the prevalence 
of OC use is estimated to be 40-50%10-11, however 
the most recent large-scale data was published in 
2005 and the use of other methods of hormonal 
contraceptives, beyond OCs, has not been reported. 
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Since this time, the use of long-acting contraceptive 
methods, such as the IUD and implant, has 
been increasing12 and therefore we suggest that 
it is important to understand not only how OCs 
in uence performance, but also how other methods 
Do hormonal contraceptives affect body composition?
of hormonal contraceptives may affect female 
athletes. ! is article will present a brief overview 
of the effects of different types of hormonal 
contraceptives on a number of factors that in uence 
athletic performance.
TABLE 1 - Characteristics of different types of hormonal contraceptives.
Type Delivery Frequency Example of brand
Contraceptive patch
! in plastic patch that 
sticks to the skin & releases 
oestrogen & progestin 
through the skin into 
the bloodstream.
New patch once a week for 3 
weeks, no patch on 4th week.
Evra®
Injectable birth control Injection of a progestin. Once every 3 months.
Depo-Provera®
Noristera®
Implantable rods
Matchstick-sized,  exible, 
& plastic rod that is inserted 
under the skin and releases 
a progestin.
5 years.
Norplant®
Implanon®
Nexplanon®
Intrauterine devices
Small, T-shaped device, 
inserted into the vagina,
that releases a progestin.
5 years.
Mirena®
Skyla®
Oral contraceptives Consumed in pill form.
Combined OCs are typically 
ingested for 21 days, followed 
by 7 non-pill taking days. 
Progestin-only pills are usually 
consumed every day.
Microgynon®
Yasmin®
Marvalon®
Cilest®
Cerazette®
Vaginal rings
Flexible plastic ring inserted 
into the vagina that releases 
oestrogen and progestin.
Worn for 21 days, removed 
for 7.
NuvaRing®
Body composition is an important determinant 
of athletic performance; excess fat mass can impair 
performance by negatively a ecting the power-
to-weight ratio13, reducing speed and agility14, 
limiting the availability of lean mass in weight 
category sports13 and hindering aesthetic sports15. 
Hormonal contraceptives are widely purported 
to induce weight gain by athletes16 and the 
general population17 although systematic reviews 
of combined contraceptives18 and progestin-
only contraceptives17 have reported inconsistent 
 ndings. In the general population, several studies 
have shown that the Depot Medroxyprogesterone 
Acetate (DMPA) injection increases fat mass when 
compared to combined OC use19-20 and non-
hormone controls19, 21. Levonorgestrel IUD use 
resulted in a 2.5% increase in fat mass after 12 months 
usage, compared to a non-hormonal copper based 
(TCu380A) IUD group who lost 1.3% fat mass22 
and Levonorgestrel implant (Norplant) use resulted 
in signi cant increases in body mass when compared 
to non-hormone groups after 623 and 12 months24. 
! e use of an etonogestrel implant (Implanon) has 
also resulted in body mass increases of 3% over 2 
years25. ! is evidence suggests that progestin-only 
contraceptives may result in greater increases in body 
mass than combined contraceptives in the general 
population, although these data may not be applicable 
to athletes as they exercise frequently and monitor 
their dietary energy intake closely15.
In a prospective randomised-controlled study, 
Proctor-Gray et al.16 demonstrated that athletes 
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 e ability to accrue muscle mass in response to 
training is bene cial as lean body mass is related 
to performance indices such as strength, speed 
and endurance31-32. The regulation of muscle 
anabolism and catabolism is affected by many 
factors and exogenous oestrogens and progestins 
may directly in uence this process or indirectly 
influence hypertrophic adaptations by altering 
the concentrations of anabolic hormones33. In the 
general population, progestin only-contraceptives 
appear to have a negative effect on lean mass. 
Bonny et al.20 reported that women who received 
the DMPA injection lost 3.6% lean mass over 2 
years compared to a DMPA and oestradiol group 
(-1.2%), OC group (+0.6%) or control group 
with no hormones (+0.6%). Women using a 
Levonorgestrel IUD lost 1.4% of their lean mass 
after 1 year compared to a 1.0% increase in lean 
mass in women using a copper-based (Tcu380A) 
IUD22 and combined OCs have also been observed 
to have a negative e ect on lean mass compared to 
control populations19.
In athletes, Proctor-Gray et al.16 demonstrated 
that regularly menstruating runners assigned to 
a second generation OC (30 µg EE and 0.3 mg 
Norgestrel) for 2 years accrued a greater amount of 
Is there a relationship between 
hormonal contraceptives and muscle mass?
who were given a combined OC (Norgestrel; n = 
69) lost more body and fat mass and gained more 
lean mass than a control group (n = 81) not using 
hormonal contraception. Conversely, Rickenlund 
et al.26 found that 10 months OC (Levonorgestrel) 
use increased body mass (4.3%) and fat mass 
(17.3%) in oligomenorrheic participants (n = 
13) but did not signi cantly a ect eumenorrheic 
participants body composition (n = 13), despite 
mean increases of 3.0% and 3.8% for body and fat 
mass. Rickenlund et al.26 used a relatively small 
sample size and in the absence of a power calculation 
it may be that the sample size was not su*  cient to 
detect signi cant changes in body composition.  is 
highlights the need for further research before the 
relationship between hormonal contraceptive use 
and body composition is fully understood in athletes.
Although data are inconclusive for contraceptive 
use and weight-gain, mechanisms have been 
identi ed which support a role for both combined 
and progestin-only contraceptives increasing 
body mass. Synthetic progestins have been 
hypothesised to act in a glucocorticoid-like manner, 
which results in increased appetite and visceral 
fat deposition27-30. Androgenic contraceptives 
may also interfere with appetite regulation by 
suppressing the secretion of the satiating hormone 
cholecystokinin25. It is unclear whether the addition 
of oestrogens in combined contraceptives in uences 
the e ects of the progestins26. However, in both 
combined and progestin-only contraceptives there 
is a down-regulation of reproductive hormones 
which has been demonstrated to reduce basal 
metabolic rate27-28, increase visceral fat deposition29, 
increase concentrations of appetite-stimulating 
hormones30 and reduce the concentrations of 
satiating hormones30.  e combination of these 
factors suggests that contraceptive use may result 
in weight gain but this has not been demonstrated 
in athletes16, 24. 
lean mass (0.67 kg·year-1) than a control group of 
runners given no hormones(-0.10 kg·year-1).  e 
mechanisms behind these changes were not reported 
and as no indices of performance were measured 
it is unclear whether these changes resulted in 
improved performance. To date, only two studies 
have examined how OC use in uences the response 
to resistance training34-35. Nichols et al.34 assessed 
the response of athletes using various preparations 
of OCs (n = 13) and athletes not using hormonal 
contraception (n = 18) to 12 weeks of resistance 
training. Strength was improved in both groups, with 
no apparent di erences between groups, although 
this study did not control for menstrual cycle phase 
when measuring strength in the control group, 
which has been shown to a ect force production36. 
In contrast, Lee et al.35 found that non-OC users (n 
= 39) gained signi cantly more muscle mass (+3.5%) 
than OC users (n = 34; +2.1%) following a 10 
week training programme. Further di erences were 
observed within the OC group, with those taking 
low androgenicity OCs having a 2.5% increase 
compared to a 0.3% increase in high androgenicity 
OC users. It is likely that the di erences in muscle 
mass shown by Lee et al.35 of su*  cient magnitude 
to e ect overall athletic performance.  e higher 
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androgenicity progestins may have a higher a  nity 
to androgen receptors, which limits the binding 
of testosterone and thus supresses muscle strength 
gains37. These findings suggests that exogenous 
hormones may in uence the anabolic response of 
muscle to resistance exercise. 
 e myo brillar protein fractional synthetic rate 
(FSR) does not vary across the menstrual cycle38, 
however Hansen et al.39 demonstrated that females 
using a third generation OC (30 µg EE and 0.0075 
g Gestogen) had a lower FSR than second generation 
users (35 µg EE and 0.25 mg Norgestimate) 
and no hormone controls.  is suggests that the 
exogenous synthetic component of contraceptives 
can a ect protein synthesis, unlike endogenous 
female reproductive hormones. Recent evidence 
suggests that oestrogen receptors (ERα and ERβ) 
within the muscle can stimulate the proliferation of 
satellite cells via the PI3K/Akt pathway for muscle 
growth and repair33, 40. EE increases the proliferation 
of satellite cells in rat muscle tissue41, indicating that 
the synthetic component of hormonal contraceptives 
may have a direct anabolic e ect on muscle, possibly 
due to a local activation of IGF-1 pathway through 
an autocrine or paracrine manner42.
Hormonal contraceptives may indirectly in uence 
muscle metabolism by altering the concentrations 
of anabolic hormones such as testosterone, Growth 
Hormone (GH) and insulin-like growth factor 1 
(IGF-1)43. A recent meta-analysis showed that OC 
use reduced free testosterone by 61% compared to 
non-users44, possibly due to an increase in sex hormone 
binding globulin concentration, which binds to 
testosterone rendering it inactive. OC use increases GH 
concentrations45-46 with second (30 µg EE and 0.125 
mg Levonorgestrel) and fourth generation (30 µg EE 
and 2 mg Dienogest) OCs reducing concentrations 
of IGF-1, but not a ecting IGF binding protein-1 
concentrations45.  e generation of contraceptive 
in uences the response of IGF-1; 30% reduction 
following fourth generation OC use compared to 12% 
reduction following second generation use46, possibly 
as the androgenic Levonorgestrel opposes the e ects 
of oestrogen on IGF-1 concentrations. In addition, 
twelve weeks use of a transdermal oestrogen patch 
(Estraderm) and oral oestrogen (Estrace) has also been 
shown to increase GH release47. It is currently unclear 
if these di erences in anabolic hormone concentrations 
with di erent methods of contraception in uence the 
response to strength training in female athletes.
A cross-sectional study found poorer handgrip force 
production and endurance in OC users (8 di erent 
types) than eumenorrheic controls48. However, studies 
comparing pill-taking days and non-pill taking days 
have generally found no di erence in strength at 
these time points49-52, although there is some limited 
evidence that strength is greater on non-pill taking 
days53. Lebrun5, using a prospective research design, 
reported no di erence in knee  exion and extension 
strength after 2 months of  rst generation OC use. To 
date, no research has been conducted assessing muscle 
strength in progestin-only OCs or other methods of 
hormonal contraception and few studies have been 
conducted in athletic populations5, 53.
How do hormonal contraceptives inﬂ uence muscle strength?
 e reduction in free testosterone and oestrogen 
concentration with contraceptive use18, 44 may 
a ect muscle force production as both hormones 
have a non-genomic action on skeletal muscle, 
by increasing intracellular calcium concentrations 
and in uencing the contractile properties of the 
muscle54-55. Despite this, few studies have shown 
an e ect of down-regulated reproductive hormones 
on skeletal muscle force production56. Indeed, 
previous research from our group57 demonstrated 
that supra-physiological concentrations of oestrogen 
and progesterone do not in uence force production 
in non-trained women.
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Is oxygen uptake affected by hormonal contraceptive use?
Many studies have shown that OC use results 
in a significant reduction in maximal oxygen 
uptake (VO
2max
) in non-athletic women after 2-6 
months use53, 58-62 which is reversed when OC use 
is terminated58, 60.  is may be due to a reduced 
activation of the sympathetic nervous system in 
ovarian suppressed women63 or a reduction in 
mitochondrial citrate58. However, other more recent 
studies have found no e ect of OC use on VO
2max 
in athletes64-65, possibly due to the use of di erent 
formulations of OC or the training status of the 
participants.
What are the effects of hormonal contraceptives 
on performance tests?
Bryner et al.60 detected a 7% reduction in VO
2max
 
with OC use (35 µg EE, 1 mg Norethindrone), 
although this had no e ect on performance in a 
treadmill running exercise capacity test. Similarly, 
Joyce et al.62 observed a reduced VO
2max
 in OC users 
compared to eumenorrheic controls; however there 
was no di erence in cycling capacity performance. 
In addition, no di erences were observed in rowing 
exercise capacity65 or 200 m swim performance66 
at di erent stages of the OC cycle in well-trained 
athletes. In a prospective study, Rickenlund et al.26 
measured endurance capacity, isometric quadriceps 
strength and handgrip strength in 26 female endurance 
athletes (13 eumenorrheic and 13 oligo-amenorrheic) 
before and after 10 months treatment with an OC 
(30 µg EE and 150 µg Levonorgestrel).  ere was no 
e ect of OC consumption, except a small decrease 
in exercise capacity in the initially oligo-amenorrheic 
group, although this may have been due to the inferior 
response to training observed in ovarian/energy 
suppressed athletes67. Further studies using exercise 
performance tests are needed, as the majority of past 
research has examined exercise capacity tests, which are 
not as ecologically valid as performance tests.
Final considerations
As we have demonstrated in this paper, it is di  cult 
to determine the role of hormonal contraceptives 
on performance as the majority of studies are 
cross-sectional and there is a paucity of prospective, 
randomised-controlled trials.  is is especially true 
for studies using progestin-only contraceptives, which 
have barely been considered in the general population 
and have not been studied at all in an athletic 
population (TABLE 2). A large number of studies 
have compared pill-taking days to non-pill taking 
days, even though data from our laboratory has shown 
there is no signi cant di erence in hormone pro le 
between these conditions68. Moreover, di erent pill 
types and formulations are often grouped together 
making it di  cult to discern possible e ects, as the 
potency and androgenicity of the synthetic hormones 
may in@ uence the response7 and we have previously 
demonstrated that the hormonal pro le is a ected by 
the brand of hormonal contraceptive68. 
It appears that the effects of hormonal 
contraceptives observed in the general population 
are not apparent in athletes, however further 
research is required to assess this. In the case of 
body composition, it may be that athletes respond 
di erently to hormonal contraceptives, as athletes 
exercise more frequently and monitor their dietary 
intake more carefully15. In terms of muscle mass, the 
increased habitual exercise level and loading in athletes 
may provide a greater stimulus for muscle anabolism, 
which may di erentiate the two populations.  ere 
may be complex interactions between direct and 
indirect e ects of hormonal contraceptive on the 
anabolic response of muscle to resistance exercise, 
however these e ects are currently unclear.  e acute 
e ects of hormonal contraceptives are more apparent 
with the majority of studies observing no e ect on 
muscle strength or performance, despite reductions 
in VO
2max
. We believe that additional studies on the 
e ects of progestin-only contraceptives on muscle 
strength and VO
2max
 are needed as this area has not 
been evaluated and newer formulations of OCs 
should be incorporated into research. 
1092 • Rev Bras Educ Fís Esporte, (São Paulo) 2016 Out-Dez; 30(4):1087-96
Martin D & Elliott-Sale K.
A summary of the effects of hormonal contraceptives on determinants of athletic performance.
P r o g e s t i n - o n l y 
contraceptives have 
been grouped together 
due to the paucity of 
research  on  these 
contraceptive delivery 
systems in athletes.
TABLE 2 -
Determinants of 
athletic performance
Combined oral contraceptives Progestin-only contraceptives
Body composition Con icting data showing combined 
oral contraceptive use both increased 
and reduced body mass and fat mass in 
athletes16, 26.
Several reports of negatives e ects in the 
general population although no studies 
have been conducted in athletes19-25.
Muscle mass accretion Combined oral contraceptive use may 
have a positive or negative e ect on 
strength gains depending upon the 
progestin used16, 19-20, 34-35.
Insu  cient evidence, although the type 
of progestin-used may in uence the 
anabolic response of muscle to resistance 
exercise20, 22.
Muscle strength  e majority of studies have reported 
no acute e ects of combined oral 
contraceptives on muscle strength49-52.
Insu  cient evidence to draw a 
conclusion.
Oxygen uptake Combined oral contraceptive use may 
reduce VO
2max
 although this is less 
apparent in trained athletes58-65.
Insu  cient evidence to draw a 
conclusion.
Performance tests Combined oral contraceptives do not 
appear to acutely e ect exercise capacity 
or performance tests26, 60, 62, 65-66.
Insu  cient evidence to draw a 
conclusion.
It is also useful to note that few studies address 
the issue of sample size and power, with only a small 
number of studies with athletic participants reporting 
priori power analysis52, 62, 64. This issue makes it 
di  cult to conclude either the statistical or clinical 
signi cance of many of the studies included in this 
overview, however it is clear that further research on 
the e ects of hormonal contraceptives is warranted 
and should not be con ned to oral contraceptives 
only. In particular, we propose that the e ects of 
long-acting, reversible, progestin-only contraceptives 
should be considered as their prevalence is increasing 
and these are likely to have different effects on 
performance than combined contraceptives.
This perspective also highlights the lack of 
information pertaining to the prevalence of hormonal 
contraceptive use in athletes. It would be bene cial 
to know the extent of hormonal contraceptive use 
in athletes so that future research can be directed 
appropriately. For example, in the general population 
the patch and ring are very rarely used: 0.1% use for 
patch and no recorded use of vaginal ring in 194,000 
participants9, therefore if athletes show a similar trend 
for usage, it may not be justi ed to recommend 
research into their e ects in an athletic population. 
However, if athletes show an increased use of the 
patch or ring than the general population, then the 
composition of these contraceptives (exposure to 
ethinyl estradiol with the nuvaring is 3.4 times less 
than the contraceptive patch and 2.1 times less than 
OCs.69 may indicate the need for more research. 
 erefore, we strongly recommend that research 
into the prevalence of hormonal contraceptive use 
in athletes should be conducted.
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Resumo
Uma perspectiva sobre a investigação dos efeitos dos contraceptivos hormonais sobre os fatores deter-
minantes do desempenho de mulheres atletas
Os métodos contraceptivos hormonais são usados por aproximadamente metade das atletas do sexo 
feminino e podem afetar o desempenho atlético como resultado de sua ação hormonal sistêmica. Nas 
atletas, o uso de anticoncepcionais parece ter pouco efeito sobre a composição corporal, porém novos 
estudos são necessários para avaliar os efeitos dos contraceptivos derivados apenas de progestina, pois 
podem ter um efeito negativo na população em geral. O tipo de progestina contido dentro do con-
traceptivo pode inﬂ uenciar a resposta anabólica do músculo, embora esta relação seja complexa em 
virtude dos efeitos diretos ou indiretos de hormônios exógenos na síntese da proteína e na proliferação 
das células satélites. A resposta sistêmica hormonal alterada em usuárias de contraceptivos parece não 
inﬂ uenciar a força muscular e, embora o consumo máximo de oxigênio às vezes seja reduzida, isso não 
afeta as medidas de desempenho. A maioria das pesquisas utilizou desenhos transversais e/ou agrupou 
diferentes tipos e marcas de anticoncepcionais hormonais e poucos estudos têm sido realizada sobre 
anticoncepcionais com progestina em atletas. Futuros estudos devem usar desenhos experimentais 
prospectivos, randomizados e controlados para avaliar os efeitos de todos os tipos de contraceptivos 
hormonais no desempenho atlético em mulheres.
PALAVRAS-CHAVE: Estrogênio; Progestina; Exercício; Composição corporal; Contraceptivo oral.
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